Explore the Category
This is the first in a two part series on the main issues raised by the annual report from the Registrar for Medical Schemes.
What do new drug pricing regulations mean for medical scheme members?
The advent of the Risk Equalisation Fund in 2005/6 has placed renewed focus on managed healthcare as one of the major areas for cost differentiation amongst medical schemes in the future.
While the new medicine pricing regulations may appear to have increased the financial burden for consumers and medical scheme members, the longer-term overall effect will be positive with a definite reduction in medicine prices.
The strongest deterrent against FSP compliance missteps is or should be: